Clinical Brochures

At Eurofins Viracor, our Fighting Fungals brochure highlights our robust fungal testing menu, differential testing capabilities, and commitment to delivering faster results to aid in anti-fungal therapy monitoring. We understand the critical nature of invasive fungal diseases (IFDs), particularly among immunocompromised patients such as organ transplant recipients, HIV/AIDS patients, and those battling cancer. Our advanced diagnostics enable early detection and precise treatment strategies, empowering healthcare providers...

The NeXGen Hybrid-capture Fungal/AFB NGS assay is revolutionary because it simultaneously sequences billions of DNA fragments, enabling the detection of unique genomic information from multiple microorganisms at once.

Eurofins Viracor's comprehensive assays include BAL specimen type analysis. Our cutting-edge technology and expertise ensure accurate and timely results for respiratory infections, including viral, bacterial, and fungal pathogens. With a focus on precision and efficiency, our BAL testing services empower healthcare providers with valuable insights to guide optimal patient care decisions.

Nontuberculous mycobacterial infections are now more commonly detected than tuberculosis in the United States, due to rising prevalence numbers along with a greater awareness due to improvements in detection, culture, and diagnosis.

Nontuberculous mycobacteria (NTM) refers to all the species in the family of mycobacteria that may cause human disease, but do not cause tuberculosis (TB) or leprosy. In a U.S. study from 2010, it was estimated.

The Eurofins Viracor Test Menu provides a comprehensive directory detailing available diagnostic tests, including those for infectious diseases, allergies, and transplant-related conditions. It outlines test names and specimen requirements, including accepted specimen types, collection instructions, turnaround times, and more, aiding healthcare providers in selecting appropriate tests. The document also highlights the company's advanced diagnostic capabilities, including molecular and serological assays, with a focus on delivering fast, accurate results.

For Hematology/Oncology patients the ExPeCT^TM anti-CD19 (FMC63) CAR T assay provides interventional data which may provide information on the expansion and persistence of the genetically modified T-cells used as therapeutic treatment for specific lymphomas and leukemias (Chimeric Antigen Receptor T-cell therapy or CAR T). Eurofins Viracor has developed and validated a multiplexed quantitative real-time PCR (qPCR) assay targeting FMC63 for the longitudinal monitoring of CD19-directed CAR T-cell therapy.